FHA
AERI

First Horizon Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

First Horizon Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-257
Closed -$2K – 2494
2021
Q3 		$2K Buy
+257
New +$3.76K ﹤0.01% 2040

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

First Horizon Advisors's AERI Position: Q4 2021 in Review

First Horizon Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 257 shares — an estimated $2K sold.

First Horizon Advisors first reported a position in AERI in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

  • First Horizon Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • First Horizon Advisors sold 257 Aerie Pharmaceuticals shares in Q4 2021, an estimated $2K.
  • First Horizon Advisors first reported a position in Aerie Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • First Horizon Advisors's Aerie Pharmaceuticals position peaked at $2K in Q3 2021.
  • 129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on First Horizon Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.